Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a randomized double-blind placebo-controlled study of BOL-DP-o-03 for painful diabetic neuropathy
MOH_2018-08-05_003563Phase 2Completed
- Sponsor
- BOL Pharma
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BOL-DP-o-03, cannabidiol and dronabinol in diabetic neuropathy (2 arms), sponsored by BOL Pharma. Primary endpoints: Pain reduction and Safety and tolerability. Started May 2018; status: completed.
02
Drugs
BOL-DP-o-03cannabidioldronabinol
03
Conditions
diabetic neuropathy
Beyond the preview
Go deeper on MOH_2018-08-05_003563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-08-05_003563.